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1. Introduction 
Neurotoxins produced by the Clostridium genus are the cause of botulism, a neuroparalytic 
disease (Dembek et al., 2007). Besides Clostridium botulinum, strains of other species such as 
Clostridium argentinense, Clostridium baratii and Clostridium butyricum can also produce 
botulinum neurotoxins (BoNTs) (Aureli et al., 1986; Hall et al., 1985). BoNTs are a complex 
containing the neurotoxin itself (molecular weight of 150 kDa) and its associated non-toxic 
proteins (Cai et al., 1999; Inoue et al., 1996). After synthesis, BoNTs are activated by a 
protease, forming a di-chain molecule consisting of a heavy chain (HC) (100 kDa) and a light 
chain (LC) (50 kDa) linked by a disulfide bond (Singh, 2000). At its C-terminus, the HC 
binds to the presynaptic membrane through gangliosides and a protein receptor (Cai et al., 
2007). The toxin is then internalised by endocytosis whereby the HC N-terminus aids the 
translocation of the LC into the cell cytoplasm (Montecucco & Molgo, 2005; Simpson, 2004; 
Singh, 2006). The internalised LC is then able to block the release of acetylcholine by 
inhibiting the fusion of synaptic vesicles with the plasma membrane (Montecucco & Molgo, 
2005; Simpson, 2004; Singh, 2006; Singh, 2000). This is done by cleaving and thereby 
inactivating the enzymes that carry out the fusion of synaptic vesicles.  
BoNTs are the most potent biological toxin known (Arnon et al., 2001; Gill, 1982). There are 
seven BoNT serotypes, A through G, which are structurally related but antigenically 
different proteins (Dembek et al., 2007; Wictome et al., 1999). Botulinum neurotoxin A 
(BoNT/A) is the most potent of the seven serotypes (Poras et al., 2009). For example, just 
one gram of BoNT/A crystalline toxin, when evenly dispersed and inhaled, would kill more 
than one million people (Arnon et al., 2001; Hicks et al., 2005). From extrapolation of animal 
studies, an estimated human dose (assuming a 70-kg person) of BoNT/A that is lethal to 
50% (LD50) of a population exposed is approximately 0.09 to 0.15 g intravenously or 
intramuscularly, 0.70 to 0.90 g by inhalation and 70 g orally (Gill, 1982; Schantz & 
Johnson, 1992; Scott & Suzuki, 1988). There are no currently licensed vaccines available to 
prevent botulism. An investigational vaccine, pentavalent botulinum toxoid (PBT), is 
accessible only to people who are deemed to be at high-risk, such as laboratory workers and 
military personnel (Bossi et al., 2004).  
The extreme potency and lethality, the ease of distribution, and the need for prolonged 
intensive care among affected individuals make BoNTs ideal bioterror agents and 
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bioweapon threats. A deliberate release of BoNTs in a civilian population may originate 
from a point-source aerosol release or contamination of a food supply. If successful, such 
bioterrorist attack would very likely overwhelm the existing public health system (Dembek 
et al., 2007), leading to public fear and social unrest (Cai et al., 2007). As a result, the US 
Centers for Disease Control and Prevention (CDC) has classified BoNTs as one of the six 
highest risk threat agents (Category A agent) for bioterrorism (Arnon et al., 2001). Like 
many other biological threats, rapid detection of BoNTs, in particular in the environment, 
food and/or clinical samples, is crucial not only to aid in early supportive care for those 
affected, but also as the key in minimising and managing the impact of a bioterrorism attack 
involving such potent toxins. 
Currently, the mouse bioassay is the widely accepted standard and approved test for 
laboratory confirmation of botulism (Barr et al., 2005; Ferreira et al., 2003; Kautter & 
Solomon, 1977; Sharma et al., 2006; Sugiyama, 1980). In this assay, mice after being given 
suspected BoNT samples were observed for symptoms of botulism for a period up to four 
days (Barr et al., 2005; Kulagina et al., 2007). Although sensitive, the mouse bioassay is 
cumbersome, time–consuming and expensive, and it also presents an ethical dilemma due 
to the use of large numbers of laboratory animals (Lindstrom & Korkeala, 2006; Varnum et 
al., 2006). As a result, there has been a concerted effort over the last few decades to develop 
alternative detection methods, some of which have surpassed the detection limit of the 
mouse bioassay (Lindstrom & Korkeala, 2006). The majority of these alternative assays are 
immunoassays, and the specificity and sensitivity of the assays are greatly dependent on the 
quality of the antibodies used. 
In this chapter, we describe the development of a new immunoassay based on a surface 
plasmon resonance (SPR) biosensor for the detection of botulinum toxin serotypes A and B, 
using formalin-inactivated toxoids (BoTds). We demonstrate that the SPR assay does not 
cross-react with other closely-related BoTds, and is able to detect BoTds in environmental 
aerosol samples. 
2. Surface Plasmon Resonance technology 
Surface plasmon resonance (SPR) is a biophysical method that monitors real-time 
biomolecular interaction of two interacting molecules (often named ligand and analyte). 
Besides real time detection, SPR technology is also able to offer kinetic parameters of the 
measured biomolecular interaction. It allows the direct determination of separate association 
(ka) and dissociation (kd) rate constants; only a few techniques to date are able to offer this 
kind of information (Hahnefeld et al., 2004). The knowledge of separate ka and kd rate 
constants is valuable in characterising and selecting the most effective binding partners 
whether they are for applications of drug discovery or detection. Another major advantage 
of the SPR over other traditional methods is its label-free detection. Fluorescence and 
luminescence detections in enzyme-linked immunosorbent assays (ELISA) or radioactive 
labelling in radioimmunoassays (RIA), in some cases, may not seem favourable, as the 
labelled tag may occupy important binding sites or cause steric hindrance which could 
interfere with the biomolecular recognition and interaction events (Gopinath, 2010). Another 
drawback in labelling of materials for biomolecular interaction is the additional steps 
required; some can be difficult.  
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SPR enables real time monitoring of a binding event between an immobilised ligand and a 
free flowing analyte in solution. It is the measurement of this interaction that underpins the 
basis of how a SPR biosensor works. To understand the optical phenomenon of SPR, one 
must understand the physics of light and its behaviours under certain conditions. When a 
beam of light at a particular angle (termed as the angle of incidence, ) strikes at the 
interface of two materials with different refractive indices; one material (glass) having a 
refractive index higher than the other material (biological buffer solution), the light is 
completely reflected. This is known as total internal reflection. This total internal reflection 
continues until the angle of incidence reaches a critical angle, C; at this angle some of the 
light is refracted across the interface (Figure 1a). If a semi-transparent noble metal (in this 
example, gold) film is thinly coated on one side of the glass surface (the side that is exposed 
to buffer solution) then under conditions described above for total internal reflection, 
surface plasmon resonance can occur. The reason is that at a particular light incident angle, 
known as the surface plasmon resonance angle, spr, total internal reflection will not occur 
(Figure 1b), because some of the light energy is ‘transferred’ to the metallic gold film. If the 
intensity of the reflected light is plotted against the angle of incidence, we will observe that 
at spr angle the intensity of reflected light is at its minimum (Figure 1c).  
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Fig. 1. Schematic diagram of surface plasmon resonance phenomenon. The refractive indices 
of glass and buffer solution are n1 and n2, respectively; where n1 > n2. Refracted beam at the 
critical angle, θc, is shown in red. At angles greater than θc, light is completely reflected (a). 
When a thin metallic gold film is coated onto one side of the glass surface, at the surface 
plasmon resonance angle, θspr, light will not be completely reflected (b). Instead, some of the 
light energy is transferred to the gold film causing a drop in the intensity of the reflected 
light at θspr angle (c).  
The spr angle is sensitive to a number of factors such as the incident light wavelength, the 
nature and thickness of the conducting film and the temperature (Hahnefeld et al., 2004). If 
all these factors are kept constant, then any shift in the spr angle will purely be dependent 
on the refractive index of the buffer solution medium at close proximity to the interface. 
Changes in the refractive index of this medium during binding events of immobilised 
ligands and free flowing analytes can then be closely monitored via any shifts in the spr 
angle by a photo-detector array equipped as a biosensor instrument. The measurement of 
the photo-detector array can be visually plotted (Figure 2a). The biosensor instrument 
processor would convert and quantify these small changes in the spr angle to absolute 
resonance units or response units (RU), and plot them against time as sensorgrams (Figure 
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2b), where 1 RU is equivalent to a small change in the spr angle of about 10-4 degrees 
(Hahnefeld et al., 2004).  
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Fig. 2. Schematic illustration of a surface plasmon resonance biosensor. The direction flow of 
analyte solution is as indicated. As analytes come into contact with immobilised ligands, 
associations (ka) and dissociations (kd) between the molecules occur. These binding 
interactions, monitored in real time, will shift the θspr angle from I to II – visually plotted as 
reflected light intensity against angle of incidence (a). The biosensor will process this change 
in θspr angle to absolute resonance or response units (RU) and plots the result as a 
sensorgram (b).  
SPR-based biosensors have been used increasingly in the past decade, especially in the post-
genomic era where the need to understand the function of biologically important molecules 
are ever increasing (Gopinath, 2010). The technology is widely used to generate bio-
recognition information from protein-protein, lipid-protein, nucleic acids and molecular 
interactions. This information will aid in the screening, discovery and development of 
therapeutic antibodies and new drugs, the detection and analysis of human pathogens and 
toxins; and also as a research tool in aptamer selection, epitope mapping, antibody 
development, ligand fishing and mutant analysis to name a few.  
In any application of SPR technology, a single or multiple ligands of interest will need to be 
firstly immobilised onto the surface of a sensorchip. Ligands can be chemically immobilised 
onto the sensorchip surface by covalent coupling via primary amines, aldehydes or reactive 
thiols. Alternatively, high-affinity and specific capture of ligands can also be performed via 
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streptavidin interactions, fusion tags, interactions between antibodies or ligand-specific 
interactions. This step aims to change the surface chemistry in preparation for subsequent 
interaction with injected free-flowing analytes. When analyte solution is flown over ligands; 
immobilised or captured, the interactions between the molecules are monitored in real time. 
A sensorgram is shown in Figure 3, three phases are involved in a typical biomolecular 
interaction study on a SPR biosensor.  
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Fig. 3. A typical SPR sensorgram showing the three phases involve in a biomolecular 
interaction study. The three phases are: association, dissociation and regeneration.  
These phases are association, dissociation and regeneration. Understanding the events and 
significance of each phase is important, as they are required in obtaining kinetic data about 
the interaction; such as the association (ka) and dissociation (kd) rate constants as well as the 
apparent equilibrium binding constant (kD or kA). In an SPR experiment, biomolecular 
interaction analysis can only be performed after a stable sensorgram baseline is achieved 
with continuous running buffer flown over immobilised or captured ligands. In the 
association phase, an analyte solution is injected and flown over the ligand surface where 
biomolecular interaction between the two, if exists, will occur. This interaction is amplified 
by an increase in the response unit (RU) on the sensorgram as shown in Figure 3. As more 
interactions take place between analytes and ligands this will also translate to a 
corresponding increase in the RU on the sensorgram, which will continue until it reaches its 
highest binding RU value, usually at the end of an analyte injection. This highest RU 
sometime can also be the maximum binding capacity (Rmax). This occurs when analytes are 
fast and strong binders to the ligand causing these analytes to fully occupy all available 
ligand binding sites.  
Dissociation phase starts when the injection of the analyte solution stops and the system 
switches to continuous flow of running buffer. Under this condition, dissociation between 
analytes and ligands is greatly favoured over association. As analytes dissociate from 
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ligands, this event is reflected by a decrease in RU on the sensorgram as shown in Figure 3. 
In many cases, analyte dissociation is never complete or it takes far too long to observe 
complete dissociation. Hence, an additional step to aid this process may be incorporated 
into the regeneration phase, which involves the injection of an appropriate regeneration 
solution to remove excess bound analytes that have not yet dissociated. The ultimate goal is 
to elute non-covalently bound analytes but at the same time not adversely disrupt the 
biological activity of the ligand in the process. At the end of the regeneration phase, a 
baseline RU is reached and ready for subsequent use, hence saving time and resources. 
However, it is often that ideal regeneration conditions are hard and time consuming to 
establish, in which cases it may be more effective to settle for non-ideal regeneration.  
3. Reagents and instruments used for assay development 
Several anti-BoNT rabbit polyclonal antibodies (PAb), purchased from Metabiologics Inc 
(Wisconsin, USA), were used as the ligands in this study; they were Anti-BoNT/A PAb (Lot. 
No. A011708-01) and Anti-BoNT/B PAb (Lot No. B082203-01), each supplied in 100 mM 
Tris/glycine buffer (pH 7.9). Purified botulinum toxins (BoNTs) and formalin-inactivated 
toxoids (BoTds) (also from Metabiologics Inc) were used as the analytes, including BoNT/A 
(Lot No. A031009-01), BoNT/B (Lot No. B031009-01), BoTd/A (Lot No. A090805-01) and 
BoTd/B (Lot No. B090705-01). The toxins were supplied in 0.22 m filtered phosphate-
buffered saline (PBS) (pH 7.0). All toxins and antibodies were kept refrigerated before use.  
For enzyme linked immunosorbent assay (ELISA), the following buffers were prepared: 
coating buffer [0.05 M carbonate-bicarbonate buffer, pH 9.6]; wash buffer [PBS containing 
0.05% Tween 20 (PBST)]; blocking solution and reagent diluent [3% skim milk in PBST 
(M-PBST)]. Substrate para-nitrophenyl phosphate (pNPP) tablets were purchased from 
Sigma-Aldrich (Sydney, Australia). A working volume of 100 l per well was used in the 
ELISA, except for the blocking step, which was 350 l per well. BoNTs or BoTds, diluted in 
coating buffer, were coated onto the wells of a Nunc-Immuno MaxiSorp microtitre plate 
(Invitro Technologies, Melbourne, Australia, cat. no. 43954) and incubated overnight at 4°C 
(~ 16 hours). Antibodies were subsequently added, all of which were diluted in M-PBST. 
Incubations of primary (anti-BoNT PAb at 0.5 g/ml) and secondary (anti-rabbit IgG-AP 
diluted 1:10,000) antibodies were carried out for 1 hour at room temperature with shaking. 
After each incubation step, the plate was washed with PBST (3 X 350 l per well). The final 
washing step (after anti-rabbit IgG-AP incubation) involved PBST washes (3 times) and a 
distilled water wash. This was followed by the addition of substrate solution. Substrate 
incubation was 1 hour at room temperature with shaking before the plate was read at 
wavelength 405 nm.  
The instruments used included the SPR BIAcore® X (GE Healthcare, NSW, Australia), 
Labsystems Wellwash Mk2 plate washer (Pathtech, Melbourne, Australia), Ratek plate 
shaker (Ratek Instruments, Melbourne, Australia) and Labsystems Multiskan Ascent 
Photometric plate reader (Pathtech, Melbourne, Australia). The BIAcore® X system 
comprises the BIAcore® X instrument, BIAcore® X Control Software (Version 2.2) and 
BIAevaluation software (Version 4.1). The following reagents were also purchased from GE 
Healthcare: CM5 sensor chip (research grade), HBS-EP running buffer (0.01 M HEPES pH 
7.4, 0.15 M NaCl, 3 mM EDTA and 0.005% v/v Surfactant P20), and amine coupling kit 
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containing 115 mg/ml N-hydroxysuccinimide (NHS), 750 mg/ml 1-ethyl-3-(3-
dimethylamino-propyl) carbodiimide hydrochloride (EDC) and 1.0 M ethanolamine-HCl, 
pH 8.5. All other chemicals used for buffer preparations were purchased from Sigma-
Aldrich (Sydney, Australia).  
4. Surface functionalisation 
In the SPR assay system, specific antibodies need to be immobilised onto the surface of a 
SPR sensor chip in order to create favourable surface chemistry that is necessary for 
interaction between BoTd and its antibody. In this study, commercial PAbs produced in 
rabbits immunised with BoNT/A and BoNT/B were immobilised onto a CM5 sensor chip. 
Firstly, carboxymethylated dextrans covalently attached to the gold surface of the sensor 
chip were activated by chemical treatment to form N-hydroxysuccinimide esters. This was 
performed with an injection (35 l) of a mixture of equal volumes of EDC and NHS at a flow 
rate of 5 l/min. This activation permitted the reactive succinimide ester surface to 
covalently bind injected anti-BoNT PAbs (50 l at concentration of 50 g/ml diluted in 
immobilisation buffer, 10 mM sodium acetate, pH 4.5) via its free amino groups. A final 35 
l injection of 1 M ethanolamine, pH 8.5 was passed over the sensor chip surface to 
deactivate and block residual active esters from any further reaction.  
The assay procedure involved injecting a continuous flow of sample solution (50 l at a flow 
rate of 5 l/min), over a sensor chip surface immobilised with a specific antibody. This 
sample solution first passed over a blank control channel (Flow Cell 1) before flowing over 
an anti-BoNT PAb immobilised surface channel (Flow Cell 2). Interactions between the 
injected BoTd and the immobilised anti-BoNT PAb were monitored by plotting the output 
signal as a sensorgram. During the injection period, BoTd detection could be observed in 
real-time from rising sensorgram signal. At the completion of sample injection, the final 
observed sensorgram signal in resonance units (RU) corresponded to the maximum binding 
that had occurred for a particular sample. At the chosen flow rate of 5 l/min, an assay took 
approximately 10 minutes to complete. At the completion of an assay, the sensor chip was 
regenerated for further assays. This was performed by injecting short pulses of a 
regeneration buffer over the sensor chip surface to remove non-covalently bound BoTd. The 
regeneration buffer chosen for this assay was 10 mM glycine-HCl, pH 1.75 with 0.01% (v/v) 
Tween 20. The generated sensorgram data was analysed by the BIAevaluation software 
(Version 4.1).  
5. Assay development and optimisation 
Our preliminary ELISA results revealed that the two anti-toxin PAbs could recognise both 
the native toxins and the formalin-inactivated toxoids for serotypes A and B (data not 
shown). For safety reasons, only the toxoids were used for the BIAcore® X system. Each 
CM5 sensor chip contained two flow cells, but only one of which (i.e. Flow Cell 2) had anti-
BoNT PAbs immobilised. The difference in Resonance Units (RU) obtained between pre-
ligand (anti-BoNT PAb) injection and post sensor chip deactivation indicates the amount of 
anti-BoNT PAb immobilised. As a general rule, 1 ng of immobilised antibodies per mm2 
equates to approximately 1,000 RU. For our anti-BoNT PAbs used, RU values in the range 
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of 2,500 to 3,500 RU were obtained consistently using the immobilisation conditions 
described above. This corresponds to approximately 2.5 to 3.5 ng of anti-BoNT PAbs 
immobilised per mm2 for either serotype. On the same sensor chip, Flow Cell 1 was used as 
a negative control, for which the same immobilisation procedure was carried out without 
ligand injection. This means the surface on Flow Cell 1 was activated, exposed to ligand-free 
immobilisation solution and deactivated. Flow Cell 1 was required for non-specific and 
background signal corrections as sample solution was injected onto the sensor chip flowing 
through Flow Cell 1 first and then onto Flow Cell 2.  
A flow rate of 5 l/min was selected in order to enhance binding conditions of the assay. 
This slow flow rate allowed sufficient time for the injected BoTds and the immobilised anti-
BoNT PAbs to interact. Samples containing BoTd/A or BoTd/B at various concentrations 
were each assayed in triplicate to determine the assay’s standard deviation and co-efficient 
of variation. After each sample injection, sensorgram signals (RU) at intervals of 50 l and 
100 l were recorded and plotted (Figure 4). Similar detection signals were obtained with 
each serotype SPR assay even though each sensor chip had different anti-BoNT PAbs 
immobilised on it. As predicted, at the same BoTd concentration, SPR detection signals 
observed at 100 l of the loaded sample were greater than that of 50 l. The increase in 
detection signals obtained from injections of 100 l of sample compared to 50 l was less 
than two-fold. This increase was not deemed significant to justify doubling of the assay time 
(at flow rate of 5 l/min, an assay of 100 l injection would take 20 minutes to complete). On 
the other hand, a 50 l sample injection would only require 10 minutes to complete an 
assay and still produced considerable and observable RU signals. Therefore, it was 
concluded that a sample injection volume of 50 l, corresponding to an assay time of just 
10 minutes, would be appropriate, sufficient and beneficial for rapid detection methods 
such as this SPR assay.  
The co-efficient of variations amongst the triplicate results varied from 5% to 13% (data not 
shown). Compared to other similar SPR assays, these values were considered to be 
relatively high although they were still acceptable. Ineffective regeneration conditions could 
be a reason for this higher than expected variation. Ideally, conditions for sensor chip 
regeneration should be such that they are harsh enough to dissociate all bound analytes 
while at the same time having minimal to neutral effects on immobilised antibodies of the 
assay. Despite repeated efforts, the final procedure developed for the assay regeneration in 
this study does not appear to be optimal and effective (data not shown). This could result in 
(i) ineffective dissociation of the bound BoTds and/or (ii) partial inactivation of the anti-
BoNT PAbs immobilised on the sensor surface. Either or both of these could reduce the 
number of accessible binding sites after each regeneration cycle, hence leading to higher 
than expected variations in replicate results.  
Based on experimental results, the assay’s limit of detection (LOD) was estimated to be 
less than 50 ng of loaded BoTd amounts, for either serotype (Figure 4). For BoTd amounts 
below the LOD, RU signals were found to be in the range of 1 to 4 RU. This RU signal 
range was similar to or below that of the assay LOD signal. This indicates that the assay 
signal had reached its lower limit, hence stabilising around this RU range even at sub 
LOD levels. Compared to a blank control injection, negative RU values were often 
observed.  
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Fig. 4. SPR assay derived standard curves for BoTds; serotypes A (A) and B (B). Error bars 
are mean  standard deviation where n = 3.  
6. Detection of environmental samples and cross-reactivity 
Environmental aerosol samples were collected at different Melbourne sites using a 
horizontal wet wall cyclone (HWWC). The cyclone is a large volume air sampler that 
collects ambient aerosol particles at the rate of ~800 litres of air per minute and concentrates 
these particles into a 10 ml solution. This solution, termed cyclone buffer, was made up of 
water and Tween 80 (0.01% v/v). These liquid samples were centrifuged and the 
supernatants were collected as environmental samples (ES). Five ES were assayed, each 
sample was spiked with BoTds (50 ng loading amounts). Table 1 shows that the assay could 
be used to detect BoTds, albeit with reduced sensitivity, in environmental aerosol samples. 
The reduced signals obtained from these spiked ES, compared to spiked cyclone buffer, may 
suggest inhibitory effects on assay sensitivity from ES testing.  
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Sample 
Recovery (%) 
BoTd/A BoTd/B 
cyclone buffer  100.0 (13.3) 100.0 (7.7) 
ES00338 59.3 (15.2) 72.6 (6.5) 
ES00352 45.3 (11.5) 26.3 (5.0) 
ES00285 58.7 (8.9) 51.6 (8.4) 
ES00316 59.3 (7.2) 51.6 (5.1) 
ES00304 87.3 (9.8) 90.7 (5.2) 
Table 1.BoTd-spiked environmental samples. An amount of 50 ng of toxoid was loaded onto 
the sensor chip for each sample. Percentage recovery was calculated based on spiked 
cyclone buffer signal. Each sample was assayed in duplicate. Values next to recovery 
percentage, in brackets, are the calculated percentage CV.  
A simple examination of the assay for cross-reactivity was performed by observing the 
detection signal generated by another closely related serotype toxoid, in this case, an 
injection of BoTd/A onto anti-BoNT/B PAb immobilised sensor chip, and vice-versa. 
Neither SPR assay showed any cross-reactivity with its related serotype BoTd. The RU 
signals generated are shown in Table 2. Visually, there was little or no cross-reactivity in 
either SPR assay, as illustrated by the respective sensorgrams, shown in Figure 5.  
 
Immobilised Sensor Chip 
RU signal 
BoTd/A BoTd/B 
Anti-BoNT/A PAb  22.0 2.3 
Anti-BoNT/B PAb 3.6 44.0 
Table 2. SPR assay cross-reactivity testing using toxoids BoTd/A and BoTd/B, each loaded 
at 250 ng onto the sensor chip.  
 
 
Fig. 5. SPR assay sensorgrams showing minimal cross-reactivity for (A) toxoid BoTd/A and 
(B) BoTd/B. 
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7. Estimation of assay sensitivity for active toxins 
To estimate the sensitivity of the SPR assay to detect active toxins, ELISA was used to 
evaluate the two anti-BoNT PAbs used in the SPR assay for their relative binding affinities 
to the toxins and their toxoids. Toxins BoNT/A and BoNT/B and their corresponding 
toxoids were coated separately onto the wells of microtitre plates. These analytes were then 
assayed using their respective anti-BoNT PAbs. ELISA detection signals, measured as 
optical density (OD) at 405 nm, at various BoNT and BoTd concentrations were plotted for 
comparisons. Typical ELISA signal curves of BoNTs and BoTds are shown in Figure 6. The 
anti-BoNT PAbs were found to have a higher binding affinity for the toxins than for the 
toxoids for both serotypes. Based on the data obtained, both BoNTs were calculated to be at 
least 40-fold more reactive than their counter-part BoTds with the anti-BoNT PAbs. This was 
to be expected because the anti-BoNT PAbs were raised specifically against the BoNTs, 
hence they recognised the BoNTs more favourably and effectively than the BoTds. From the 
correlation curves, the detection limit of our SPR assay of 50 ng for toxoids can be estimated 
to an approximate amount of 1.3 ng for BoNTs.  
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Fig. 6. Correlations in detection sensitivity between toxin BoNT/B and toxoid BoTd/B. 
ELISA signal, OD at 405 nm, plotted against coated toxin or toxoid concentrations.  
The stability of the toxins stored at 4 °C was also investigated. It was found that ELISA signals 
obtained for 5 ng/ml of coated toxins were gradually reduced over a period of a year, despite 
refrigeration storage of the toxins. The signals reduced significantly, more than 50 percent, 
within 6 months of toxin production and it appeared that the rate of degradation was greater 
for BoNT/A than for BoNT/B (data not shown). This is in agreement with other publications 
that BoNT itself is less stable than BoNT complex (Brandau et al., 2007). The complex consists 
of BoNT and its non-toxic associated proteins, which is believed to protect the neurotoxin 
against damage from exposure to extreme conditions. The increased thermal stability of the 
BoNT complex may have risen from the internal structure of the complex generated by 
interactions between BoNT itself and the associated non-toxic proteins (Brandau et al., 2007).  
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8. Discussion and concluding remarks  
Here, we report the development of a real-time optical SPR assay using formalin inactivated 
toxins, BoTds. The data were then correlated back to their active toxin BoNT values by 
assessing the same anti-BoNT PAbs for their binding affinities to both BoNTs and BoTds in 
an ELISA setting. This indirect evaluation of an SPR assay for BoNT detection is less than 
ideal, but it is a requirement for the SPR instrument due to safety concerns. Unlike other 
models, the BIAcore® X does not have an enclosed sample injection compartment or an 
automatic injector. Therefore, samples need to be manually injected into the BIAcore® X in 
an open area environment where toxin aerolisation and inhalation would pose a possible 
risk.  
The SPR assay developed has several advantages over other assays in that it is rapid, 
provides real-time detection following sample injection, and requires no reagents to be 
labelled. The assay has an estimated LOD of 1.3 ng of loaded BoNTs for both serotypes, a 
value obtained based on BoTd experimental data. A similar SPR assay has been 
previously reported by Ladd et al (Ladd et al., 2008), which, however, requires at least 60 
minutes to complete an assay plus a further 2 hours for preparation prior to the actual 
assay. In comparison, our SPR assay takes only 10 minutes to complete, and in fact, the 
entire procedure from antibody immobilisation to completing an SPR assay takes less 
than 40 minutes. Furthermore, our assay does not require the preparation for antibody 
biotinylation, purification and immobilisation and the addition of another antibody to 
achieve the LOD.  
Examples of other technologies being used for BoNT detection include ELISA (Ferreira et al., 
2003; Poli et al., 2002; Sharma et al., 2006; Wictome et al., 1999; Wictome et al., 1999), mass 
spectrometry (Barr et al., 2005; Boyer et al., 2005; Kalb et al., 2005; Kalb et al., 2006), 
enzyme-amplified protein micro-array immunoassay (Varnum et al., 2006), fluorometric 
biosensor (Dong et al., 2004), and a modified immunoassay (Bagramyan et al., 2008), which 
measures the intrinsic metalloprotease activity with a fluorogenic substrate. Although some 
of these assays are more sensitive than the SPR assay, they do not offer real-time detection, 
often require antibodies to be labelled, which can create problems in antibody-antigen 
recognition, and most importantly these assays are laborious. Assays based on polymerase 
chain reaction (PCR) have also been reported; however, these assays can only detect the 
presence of residual bacterial DNA if present in BoNT samples (Fach et al., 2009; Lindstrom 
& Korkeala, 2006). Therefore, they are not applicable to toxin samples of high purity (i.e. 
toxin samples where they do not contain any residual bacterial DNA).  
The option of incorporating another antibody into our SPR assay was not investigated. This 
additional step would theoretically provide a larger SPR response, effectively amplifying the 
output signal and increasing the assay sensitivity. The significance of enhanced sensitivity 
should be investigated to determine whether the benefit warrants a longer assay time.  
Successful regeneration of sensor chip surface is critical for any SPR assay as it allows 
multiple assays to be performed. An ideal regeneration condition should be such that it 
dissociates and removes all bound molecules but does not damage the biological activity of 
immobilised antibodies on the chip. The present assay has a coefficient of variation ranging 
from 5% to 13 %, which was a rather high value compared to other SPR assays. This could 
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be caused by an ineffective regeneration of the chip surface. It was also possible that the 
immobilised antibody surface might have been damaged or that the bound BoTds might 
have not been effectively removed. Either, or both, of these would contribute to a reduction 
in the number of accessible binding sites after each regeneration cycle.  
The cross reactivity of the assay was evaluated against two closely related serotypes 
BoTd/A and BoTd/B. Although the experiment was simple and limited, our results showed 
that the assay did not cross-react with its closely related BoTd serotype, suggesting minimal 
cross-reactivity issues with other non-related toxins. Both assays also detected BoTd-spiked 
environmental samples, although all signals were reduced when compared to spiked 
cyclone buffers. The signal reduction suggests possible inhibitory effects of the sample on 
the immobilised anti-BoNT PAbs, and consequently on their assay sensitivity. Further 
studies with a larger number of environmental samples should be performed to provide 
more information concerning the detection of native toxins in different sample matrices and 
cross-reactivity with other toxins or contaminants. In addition, more stable anti-BoNT 
antibodies should be sought because like other immunoassays, the SPR assay also relies 
heavily on the use of high quality antibodies that are not only highly specific for their 
targets but are also able to withstand the harsh regeneration process.  
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